Biocon Biologics, the trailblazing global biosimilars company under the wing of Biocon, has recently garnered the esteemed approval of the US Food and Drug Administration (FDA) for two groundbreaking treatments – Bosaya and Aukelso. Bosaya, a denosumab-kyqq injection in a single-dose prefilled syringe, and Aukelso, a denosumab-kyqq injection for subcutaneous use in a single-dose vial, are hailed as the biosimilars of Prolia and Xgeva, respectively. Notably, both Bosaya and Aukelso have been granted provisional interchangeability designation by the US FDA, a significant nod to their efficacy and quality.
In a jubilant announcement, Shreehas Tambe, the CEO & managing director of Biocon Biologics, expressed profound pride in this milestone achievement. Tambe remarked, “The FDA’s approval of Bosaya and Aukelso is a significant milestone in our mission to expand access to critical biologic therapies.” With Bosaya catering to patients with osteoporosis and Aukelso enriching the oncology care portfolio, Biocon Biologics is carving a path towards affordable treatment options and enhanced patient outcomes. This regulatory triumph not only showcases the company’s scientific prowess but also underscores its commitment to delivering top-notch biosimilars that fortify healthcare systems worldwide.
Bosaya’s approval encompasses a wide spectrum of conditions, including postmenopausal osteoporosis, glucocorticoid-induced osteoporosis, and bone mass increment in men at high fracture risk. Moreover, it extends its therapeutic prowess to men undergoing androgen deprivation therapy for prostate cancer and women receiving adjuvant aromatase inhibitor therapy for breast cancer. On the other hand, Aukelso is tailored to prevent skeletal-related events in multiple myeloma patients, manage bone metastases from solid tumors, and treat giant cell tumor of bone in adults and adolescents, among other indications.
Clinical data has unequivocally demonstrated the parity in quality, safety, and efficacy between Bosaya, Aukelso, and their reference counterparts. Noteworthy is the approval of Bosaya with the same Risk Evaluation and Mitigation Strategy (REMS) plan as Prolia, emphasizing the importance of informing healthcare providers and patients about the risks associated with severe hypocalcemia, especially in patients with advanced chronic kidney disease. This proactive measure ensures the safe and informed use of the medication, aligning with Biocon Biologics’ patient-centric approach.
The impact of Bosaya and Aukelso goes beyond their innovative formulations and regulatory approvals. According to IQVIA National Sales Perspectives Data, the predecessor denosumab has amassed a staggering $5 billion in US sales, with Prolia contributing $3.3 billion and Xgeva adding $1.6 billion, underscoring the immense market potential and value of these treatments. This robust financial performance not only speaks to the commercial viability of Bosaya and Aukelso but also highlights the growing demand for advanced biologic therapies in addressing complex medical conditions.
In conclusion, Biocon Biologics’ triumph with Bosaya and Aukelso heralds a new era in osteoporosis and oncology care, offering hope and healing to patients grappling with debilitating conditions. The FDA’s stamp of approval not only validates the efficacy and safety of these biosimilars but also paves the way for enhanced access to critical biologic therapies. As Biocon Biologics continues its relentless pursuit of excellence in biosimilar development, the unveiling of Bosaya and Aukelso stands as a testament to the company’s unwavering commitment to advancing healthcare and improving patient outcomes on a global scale.
Tags: regulatory
Read more on pharmabiz.com